News

28 November 2017, Maastricht, The Netherlands – Cristal Therapeutics, a clinical stage biopharmaceutical company developing targeted nanomedicines for the treatment of cancer and other diseases with high unmet patient need, today announced that it secured a €2.5 million grant from the European Commission’s Horizon 2020 programme. (more…)

3 October 2017, Nijmegen, The Netherlands – Mellon Medical, a Dutch MedTech developer of a platform technology for suturing with one hand, has raised € 6 million to advance its patented ground breaking global innovation in suturing technology. (more…)

12-month clinical study published on NightBalance’ Sleep Position Trainer

Date: 18/09/2017

18 September 2017 – A clinical study demonstrating the excellent efficacy and compliance of the Sleep Position Trainer, NightBalance’ revolutionary device to treat positional sleep apnea, has been accepted for publication in the professional journal Sleep and Breathing. (more…)

Hemics in the news

Date: 06/09/2017

6 September 2017 – Two articles have appeared in the media related to the initial international commercial success of Hemics. They can be found here (both in the Dutch language): Sprout and Telegraaf.

Hemics goes international and sell first devices in Germany and Belgium

Date: 28/08/2017

28 August 2017, Eindhoven, the Netherlands – The HandScan, a Dutch medical technology innovation, will be used this month for the first time outside the Netherlands. Clinics in Germany and Belgium have purchased the innovative rheumatism scanner from Eindhoven start-up company Hemics. (more…)

ATRO Medical closed a Series A financing round for the development of a polymer based meniscus implant

Date: 17/07/2017

17 July 2017, Nijmegen, The Netherlands – Today ATRO Medical announces the successful closure of a Series A financing round. The funding provided by a syndicate led by Thuja Capital Healthcare (Seed) Fund II and includes Brabant Development Agency, DSM Venturing, Cascara Ventures and Radboud university medical center. (more…)

7 June 2017, Wageningen, The Netherlands – NUTRILEADS B.V., a Dutch Nutrition & Health startup, together with NIZO food research (consortium leader) and Friesland Campina, has been awarded a €3,7 million EFRO project called CHALLENGE. (more…)

argenx announces closing of NASDAQ IPO

Date: 23/05/2017

23 May 2017, Breda, the Netherlands / Ghent, Belgium – argenx (Euronext & Nasdaq: ARGX), announced today the closing of its initial public offering in the United States (the “Offering”) of 6,744,750 American Depositary Shares (“ADSs”), at a price to the public of $17.00 per ADS, for gross proceeds of approximately $114.7 million. (more…)

argenx raises approximately $100 million gross proceeds with NASDAQ IPO

Date: 18/05/2017

18 May 2017, Breda, the Netherlands / Ghent, Belgium – argenx (Euronext Brussels: ARGX, Nasdaq: ARGX) announced today the pricing of its initial public offering in the United States (the “Offering”) with anticipated gross proceeds totalling approximately $100 million from the sale of 5,865,000 American Depository Shares (“ADSs”), at a price to the public of $17.00 per ADS. (more…)

NutriLeads closes series A round to advance the development of its lead nutritional ingredient supporting immune function

21 March 2017, Breda, the Netherlands/Ghent, Belgium – argenx (Euronext Brussels: ARGX) today announced that it has entered into a new collaboration with Broteio Pharma B.V. to develop an antibody against a novel target in the complement cascade with therapeutic potential in autoantibody- and complement-mediated indications including autoimmune haemolytic anaemia (AIHA) and antibody mediated rejection (AMR) following organ transplantation. (more…)

10 January 2017, Eindhoven, The Netherlands – The regional Dutch newspaper Eindhovens Dagblad reported on Hemics installing a first Handscan device in a major Dutch hospital. (more…)

Thuja Capital leads series A investment round in Indigo Diabetes

Date: 20/12/2016

20 December 2016, Utrecht (NL) and Ghent (B) — Indigo Diabetes nv (Indigo), a spin-off from Ghent University (UGent) and imec, today announces the successful closure of a 7 million Euros series-A financing round. The funding is provided by an international investment syndicate led by Thuja Capital Healthcare Fund II (The Netherlands) (more…)

7 December 2016, Maastricht, The Netherlands and Gosselies, Belgium – Cristal Therapeutics and iTeos Therapeutics today announced a strategic partnership for the discovery, development and commercialization of optimized immuno anti-cancer drug candidates, (more…)

24 November 2016, Wageningen, The Netherlands. NutriLeads B.V. today announces the positive outcome of a proof of concept study in humans demonstrating that its lead ingredient IMPP-1 is safe, well tolerated and supports immune function in humans. (more…)

Nutrileads wins prestigious Eurostars grant

Date: 21/11/2016

21 November 2016, Wageningen, The Netherlands. NutriLeads B.V., a Dutch Nutrition & Health startup has won a prestigious Eurostars grant to support the development of its lead ingredient IMPP-1 for application in medical foods. Nutrileads (as consortium leader) and 4 partners from the Netherlands, Germany and Finland have been awarded a € 2 million (more…)

Investeringsmaatschappijen zien run op medische startups

Date: 14/06/2016

14 June 2014 – The Dutch financial newspaper Financieele Dagblad published an article (in Dutch language) about several funds that closed successfully in recent days, among which Thuja Capital Healthcare Fund II. See the original article here:FD artikel

9 June 2016, Utrecht – Thuja Capital Management (“Thuja”) has successfully closed a new venture capital fund, Thuja Capital Healthcare Fund II, with a fund size of EUR 34M. The fund will be used for investing in young Dutch and Belgian companies that develop innovative products for medical applications. (more…)

NutriLeads announces collaboration with DSM Nutritional Products

Date: 26/05/2016

26 May 2016, Wageningen, The Netherlands – Dutch nutritional health ingredients startup NutriLeads B.V. announces the signing of a collaboration agreement with DSM Nutritional Products for the further development of its lead ingredient. (more…)

28 April 2016, Maastricht, The Netherlands – Cristal Therapeutics, a privately-held life sciences company developing novel nanomedicines against cancer and other diseases, by using its patented CriPec® platform, today announced the appointment of Edwin Klumper as Chief Medical Officer. (more…)

argenx and AbbVie to collaborate on ARGX-115 against novel immuno-oncology target

argenx receives milestone payment in LEO Pharma collaboration

Date: 02/02/2016

2 February 2016, Breda, The Netherlands / Ghent, Belgium – argenx (Euronext Brussels: ARGX) today announced it has received a milestone payment in connection with its collaboration with LEO Pharma. The companies have selected a lead cell line for manufacture of the licensed SIMPLE AntibodyTM candidate, in development for the treatment of inflammatory skin conditions. (more…)

6 January 2016, Breda, The Netherlands / Ghent, Belgium – argenx (Euronext Brussels: ARGX) today announced that it has completed the dose-escalation part of a Phase 1 study of ARGX-113. (more…)

Thuja Capital Healthcare Seed Fund II invests in Nutrileads

Date: 18/11/2015

18 November 2015, Utrecht – Thuja Capital today announced that it has invested in Wageningen-based Nutrileads, a start-up company active in the field of medical and functional foods. Thuja acted as lead investor, heading a syndicate of Shift Invest, PPMOost and DSM Venturing. (more…)

arGEN-X completes first dosing of ARGX-113 for severe autoimmune disorders

29 September 2015, Maastricht, The Netherlands – Cristal Therapeutics, a privately-held life sciences company developing innovative drugs against cancer and other diseases, today announced the recent start of a clinical phase I trial with its lead candidate CriPec® docetaxel (more…)

23 September 2015, Breda, The Netherlands / Ghent, Belgium – arGEN-X N.V. (Euronext Brussels: ARGX) today reports that its partner RuiYi, Inc., a company focused on the discovery and development of novel biologic therapies (more…)

TheraSolve Announces US Patent Issuance for MemoPatch®

Date: 15/09/2015

15 September 2015, Diepenbeek, Belgium – TheraSolve NV, a medication adherence innovator, announced today patent issuance from the United States Patent and Trademark Office for its innovative MemoPatch® reminder technology. (more…)

NightBalance strengthens competitive position in sleep apnea market with key US and EU patent for innovative Sleep Position Trainer

Date: 19/08/2015

19 August 2015, Delft, the Netherlands – Today the European Patent office has granted NightBalance an important patent for their “method and device for sleep posture correction”, following the earlier grant by the US Patent and Trademark Office on July 30th 2015. (more…)

arGEN-X and University of Bern enter into license agreement

Date: 30/07/2015

30 July 2015, Breda, The Netherlands/Ghent, Belgium – arGEN-X and the Clinical Research Department of the University of Bern announce an exclusive license agreement enabling arGEN-X to develop and commercialize ARGX-110-based therapies to overcome treatment resistance mechanisms in hematologic tumors. (more…)

Supersnelle scan verlicht reumaleed

20 July 2015, Maastricht (Netherlands) – The European Union awarded FABPulous BV a €1.6 million Phase 2 grant to fund two clinical trials in the UK and Belgium/Netherlands and automate the manufacture of its 5 minute, patented H-FABP True Rapid Test® (more…)

14 July 2015, Maastricht – Cristal Therapeutics, a privately-held life sciences company developing innovative products against cancer and other diseases, by using its patented nanotechnology platforms, today announced the start of a collaboration with PX Biosolutions (Melbourne, Australia). The joint research and development is focussed on the application of Cristal Therapeutics’ vaccine technology CriVac® for the design of innovative vaccines.

The CriVac® platform enables the tailor-made development of well-characterized polymeric nanoparticles of a specific size, that allow optimal antigen presentation to dendritic cells. CriVac® is one of the proprietary nanotechnology platforms of Cristal Therapeutics, next to CriPec®.

PX Biosolutions is an Australian based company operating from Melbourne, Victoria. PX Biosolutions’ scientists have developed DCtagTM vaccine formulations against various types of cancer. These vaccine formulations have been tested successfully in animal models.

NightBalance patent for “method and device for sleep posture correction” granted by US PTO

Date: 01/07/2015

1 July 2015, Delft, the Netherlands – NightBalance BV, a leading innovator of obstructive sleep apnea (OSA) technology, announced today that the U.S. Patent and Trademark Office has granted (more…)

TheraSolve wins Biomedica 2015 Award for best Medtech Innovation

Date: 10/06/2015

9 June 2015, Diepenbeek (Belgium) – TheraSolve NV presented its MemoPatch® reminder technology at the European Life Sciences Summit Biomedica 2015 and has been elected by the members of the Biomedica Foundation Board as winner in the category Medtech. (more…)

European Investment Fund makes formal funding commitment to TCHF II

Date: 02/06/2015

2 June 2015, Utrecht – Today the European Investment Fund (EIF) has communicated a formal commitment for an investment in Thuja Capital Healthcare Fund II. The commitment amounts to EUR 15M assuming a fund size of EUR 35M. (more…)

arGEN-X presents preliminary efficacy and expanded safety data from Phase I trial of ARGX-111 at ASCO

arGEN-X awarded €1.5 million IWT grant

Date: 19/05/2015

19 May 2015 – Breda, The Netherlands / Ghent, Belgium – arGEN-X N.V. (Euronext Brussels: ARGX) today announced that it has received a € 1.5 million grant from the Institute for the Promotion of Innovation by Sciences and Technology in Flanders (IWT). (more…)

18 May 2015, Delft, the Netherlands – NightBalance announced today that Achmea, the largest healthcare payor in the Netherlands covering 5 million lives, will reimburse its Sleep Position Trainer (SPT). (more…)

Lonza and arGEN-X announce a license agreement for therapeutic antibodies

Date: 18/02/2015

18 February 2015, Breda, The Netherlands – Lonza, a global leader in biological manufacturing and arGEN-X N.V. announced today that they have entered into a new, multi-product commercial license agreement for the production of arGEN-X’s therapeutic antibodies. (more…)

4 February 2015, Maastricht – Today FABPulous announced the successful closure of their €1.8m Series B funding round by undisclosed new investors as well as some of the current investors. (more…)

Therasolve closes a EUR 2.4M series A financing round

Date: 22/01/2015

21 January 2015, Diepenbeek, Belgium – TheraSolve NV announces that it has recently closed an “A” financing round accounting for a total investment of EUR 2.4 million. (more…)

Hemics successfully closes new financing round and obtains CE marking

Date: 09/01/2015

9 January 2015, Eindhoven, The Netherlands – Hemics announces today that it received CE marking required for commercial sales of its medical device, the HandScan, and closed a new investment round, welcoming new investor DFZ Participaties. (more…)

€6 million in new capital and new CEO for Cristal Therapeutics

Date: 15/12/2014

15 December 2014, Maastricht, The Netherlands – Biopharmaceutical company Cristal Therapeutics has completed a new financing round of over €6 million (more…)

11 December 2014, Breda, The Netherlands / Ghent, Belgium – arGEN-X N.V. today announced that its partner Shire has exercised its option to advance into preclinical development one or more product candidates (more…)

3 November 2014, Breda, The Netherlands / Ghent, Belgium – arGEN-X announced today the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) to initiate a Phase 1b/2 trial of ARGX-110 (more…)

Strategic Investment by SkylineDx in Cancer Vaccine Company DCPrime

Date: 29/10/2014

28 October 2014, Rotterdam & Leiden – SkylineDx, an innovative company in the field of genetic testing for blood cancers, announced today a strategic investment of an undisclosed sum in the Dutch cancer vaccine company DCPrime. (more…)

Article in FD (Bijlage Biotechnologie)

ArGEN-X lists successfully on Euronext Brussels

Date: 10/07/2014

10 July 2014 – ArGEN-X N.V., a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, announces the successful completion of its Initial Public Offering (more…)

arGEN-X and The Leukemia & Lymphoma Society Partner on Treatment of Waldenström’s Macroglobulinemia

Date: 11/06/2014

10 June 2014, Breda, the Netherlands / Ghent, Belgium – arGEN-X today announced it has entered into a partnership with The Leukemia & Lymphoma Society (LLS) in which both parties will contribute to the funding of a Phase 2 clinical study (more…)

June 4, 2014. Ghent, Belgium/Breda, the Netherlands – arGEN-X today announced it has entered into a long-term strategic alliance with Shire Pharmaceuticals. (more…)

arGEN-X announces collaboration with Bayer

Date: 28/05/2014

28 May 2014, Breda, the Netherlands – arGEN-X announced today the initiation of a collaboration with Bayer Pharma AG (Bayer), leveraging arGEN-X’s SIMPLE Antibody™ technology for the discovery and development of therapeutic antibodies. (more…)

Thuja Capital starts new investment funds with a focus on medical product innovations

31 March 2014, Eindhoven, the Netherlands – Hemics BV announces today a multi-center clinical study to evaluate the cost effectiveness and efficacy of its HandScan in tight control treatment of rheumatoid arthritis (RA). (more…)

13 January 2014, Breda, The Netherlands / Ghent, Belgium – arGEN-X announces that it has advanced ARGX-110, a novel anti-CD70 antibody, into the safety and efficacy expansion part of its Phase Ib study. (more…)

arGEN-X receives two preclinical milestone payments under collaboration with Shire

Date: 13/01/2014

13 January 2014, Breda, the Netherlands / Ghent, Belgium – arGEN-X announces the attainment of two important success milestones in its SIMPLE Antibody™ research and product development collaboration with Shire. (more…)

17 December 2013, Breda, The Netherlands / Ghent, Belgium – arGEN-X announces that the dose-escalation part of a Phase Ib study (more…)

arGEN-X and de Duve Institute/UCL to collaborate on novel immunomodulation therapy in cancer

Date: 04/11/2013

4 November 2013, Breda, The Netherlands / Ghent, Belgium – arGEN-X today announced the signing of a research and license agreement with de Duve Institute/UCL (Belgium). (more…)

arGEN-X raises EUR 5 million from PMV in extension of EUR 32.5 million series B

Date: 04/11/2013

4 November 2013, Breda, The Netherlands / Ghent, Belgium – arGEN-X has raised EUR 5 million ($6.8 million) as an extension of its series B financing round (more…)

DCPrime and Janssen to collaborate on potential new therapy

Date: 03/10/2013

3 October 2013, Leiden, The Netherlands – Cancer vaccine company DCPrime BV today announced that it has entered into a research and optional license agreement with Janssen Pharmaceuticals, Inc. (more…)

ArGEN-X initiates clinical Phase IB study of ARGX-111 in cancer

Date: 17/09/2013

17 September 2013, Breda, the Netherlands, and Ghent, Belgium – arGEN-X announces today the CTA filing of a first-in-man Phase Ib cancer study with ARGX-111, its second proprietary SIMPLE Antibody™ product to enter the clinic this year. (more…)

22 August 2013, Leuven, Belgium – Okapi Sciences NV announces today that it has entered into an exclusive agreement with Novartis Animal Health for the joint development and commercialisation of an antiviral treatment for cats. (more…)

28 November 2017, Maastricht, The Netherlands – Cristal Therapeutics, a clinical stage biopharmaceutical company developing targeted nanomedicines for the treatment of cancer and other diseases with high unmet patient need, today announced that it secured a €2.5 million grant from the European Commission’s Horizon 2020 programme. Read further …

3 October 2017, Nijmegen, The Netherlands – Mellon Medical, a Dutch MedTech developer of a platform technology for suturing with one hand, has raised € 6 million to advance its patented ground breaking global innovation in suturing technology. Read further …

18 September 2017 – A clinical study demonstrating the excellent efficacy and compliance of the Sleep Position Trainer, NightBalance’ revolutionary device to treat positional sleep apnea, has been accepted for publication in the professional journal Sleep and Breathing. Read further …